Cure My Disease

Don't miss your cure!

 Log in / Sign up

Multiple myeloma patients get continued access to isatuximab in safety extension study

NCT ID NCT05669989

Ongoing Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study offers continued treatment with isatuximab (a targeted antibody) to adults with multiple myeloma who were already benefiting from it in earlier trials. About 70 participants will receive the drug, possibly combined with other medications, to monitor long-term safety. The goal is to ensure patients can keep accessing a therapy that works for them.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Isatuximab (with possible cemiplimab, dexamethasone, lenalidomide, or pomalidomide)

What this could lead to

If successful, this study could show that long-term isatuximab treatment is safe and continues to control multiple myeloma, offering ongoing benefit to patients.

What could go wrong

This is a small, open-label extension study (70 participants) focused on safety, not on proving new effectiveness. It may not show clear long-term benefits or apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLASMA CELL MYELOMA

Contacts and locations

Locations

  • Hospital Mae de Deus- Site Number : 0760003

    Porto Alegre, Rio Grande do Sul, 90880-480, Brazil

  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo - HCFMUSP- Site Number : 0760002

    São Paulo, São Paulo, 05403-010, Brazil

  • Instituto Americas - Ensino, Pesquisa e Inovação - Rio de Janeiro - Avenida Jorge Curi- Site Number : 0760001

    Rio de Janeiro, 22775-001, Brazil

  • Investigational Site Number : 0360001

    Saint Leonards, New South Wales, 2065, Australia

  • Investigational Site Number : 0360002

    Richmond, Victoria, 3121, Australia

  • Investigational Site Number : 0360003

    Wollongong, New South Wales, 2500, Australia

  • Investigational Site Number : 0360004

    Melbourne, Victoria, 3065, Australia

  • Investigational Site Number : 0360005

    Melbourne, Victoria, 3084, Australia

  • Investigational Site Number : 0360006

    Blacktown, New South Wales, 2148, Australia

  • Investigational Site Number : 1520001

    Temuco, 4780000, Chile

  • Investigational Site Number : 1560001

    Tianjin, 300020, China

  • Investigational Site Number : 1580001

    Taichung, 404, Taiwan

  • Investigational Site Number : 2030001

    Prague, 128 08, Czechia

  • Investigational Site Number : 2030002

    Brno, 625 00, Czechia

  • Investigational Site Number : 2030003

    Ostrava, 708 52, Czechia

  • Investigational Site Number : 2460001

    Helsinki, 00029, Finland

  • Investigational Site Number : 2500002

    Nantes, 44093, France

  • Investigational Site Number : 3000001

    Pátrai, 265 04, Greece

  • Investigational Site Number : 3000003

    Athens, 115 28, Greece

  • Investigational Site Number : 3000004

    Athens, 106 76, Greece

  • Investigational Site Number : 3800002

    Torino, 10126, Italy

  • Investigational Site Number : 3920001

    Okayama, 701-1192, Japan

  • Investigational Site Number : 4100001

    Seoul, Seoul-teukbyeolsi, 03080, South Korea

  • Investigational Site Number : 4100002

    Seoul, Seoul-teukbyeolsi, 06591, South Korea

  • Investigational Site Number : 5540001

    Wellington, 6021, New Zealand

  • Investigational Site Number : 5540002

    Auckland, 2025, New Zealand

  • Investigational Site Number : 6430001

    Moscow, 125284, Russia

  • Investigational Site Number : 6430002

    Kirov, 610027, Russia

  • Investigational Site Number : 7240001

    Pamplona, Navarre, 31008, Spain

  • Investigational Site Number : 7240002

    Salamanca, 37007, Spain

  • Investigational Site Number : 7240003

    Madrid, 28041, Spain

  • Investigational Site Number : 7240004

    Santander, Cantabria, 39008, Spain

  • Investigational Site Number : 7240005

    Badalona, Catalunya [Cataluña], 08916, Spain

  • Investigational Site Number : 7240006

    Seville, Andalusia, 41013, Spain

  • Investigational Site Number : 7241001

    Madrid, Madrid, Comunidad de, 28027, Spain

  • Investigational Site Number : 7520004

    Luleå, 971 80, Sweden

  • Washington University- Site Number : 8400001

    St Louis, Missouri, 63110, United States